The Management of Cardiovascular Risk through Epigenetic Biomarkers
Epigenetic sciences study heritable changes in gene expression not related to changes in the genomic DNA sequence. The most important epigenetic mechanisms are DNA methylation, posttranslational histone modification, and gene regulation by noncoding RNAs, such as microRNAs (miRNAs) and long noncodin...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2017/9158572 |
id |
doaj-79ada912426440a9846350e9be669bbe |
---|---|
record_format |
Article |
spelling |
doaj-79ada912426440a9846350e9be669bbe2020-11-24T21:01:11ZengHindawi LimitedBioMed Research International2314-61332314-61412017-01-01201710.1155/2017/91585729158572The Management of Cardiovascular Risk through Epigenetic BiomarkersLaurent Metzinger0Stefano de Franciscis1Raffaele Serra2CURS, Laboratoire INSERM U1088, Université de Picardie Jules Verne, chemin du Thil, 80025 Amiens Cedex 1, FranceInteruniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, Viale Europa, 88100 Catanzaro, ItalyInteruniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, Viale Europa, 88100 Catanzaro, ItalyEpigenetic sciences study heritable changes in gene expression not related to changes in the genomic DNA sequence. The most important epigenetic mechanisms are DNA methylation, posttranslational histone modification, and gene regulation by noncoding RNAs, such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). Cardiovascular diseases (CVD) are responsible for at least one-third of premature deaths worldwide and represent a heavy burden of healthcare expenditure. We will discuss in this review the most recent findings dealing with epigenetic alterations linked to cardiovascular physiopathology in patients. A particular focus will be put on the way these changes can be translated in the clinic, to develop innovative and groundbreaking biomarkers in CVD field.http://dx.doi.org/10.1155/2017/9158572 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laurent Metzinger Stefano de Franciscis Raffaele Serra |
spellingShingle |
Laurent Metzinger Stefano de Franciscis Raffaele Serra The Management of Cardiovascular Risk through Epigenetic Biomarkers BioMed Research International |
author_facet |
Laurent Metzinger Stefano de Franciscis Raffaele Serra |
author_sort |
Laurent Metzinger |
title |
The Management of Cardiovascular Risk through Epigenetic Biomarkers |
title_short |
The Management of Cardiovascular Risk through Epigenetic Biomarkers |
title_full |
The Management of Cardiovascular Risk through Epigenetic Biomarkers |
title_fullStr |
The Management of Cardiovascular Risk through Epigenetic Biomarkers |
title_full_unstemmed |
The Management of Cardiovascular Risk through Epigenetic Biomarkers |
title_sort |
management of cardiovascular risk through epigenetic biomarkers |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2017-01-01 |
description |
Epigenetic sciences study heritable changes in gene expression not related to changes in the genomic DNA sequence. The most important epigenetic mechanisms are DNA methylation, posttranslational histone modification, and gene regulation by noncoding RNAs, such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). Cardiovascular diseases (CVD) are responsible for at least one-third of premature deaths worldwide and represent a heavy burden of healthcare expenditure. We will discuss in this review the most recent findings dealing with epigenetic alterations linked to cardiovascular physiopathology in patients. A particular focus will be put on the way these changes can be translated in the clinic, to develop innovative and groundbreaking biomarkers in CVD field. |
url |
http://dx.doi.org/10.1155/2017/9158572 |
work_keys_str_mv |
AT laurentmetzinger themanagementofcardiovascularriskthroughepigeneticbiomarkers AT stefanodefranciscis themanagementofcardiovascularriskthroughepigeneticbiomarkers AT raffaeleserra themanagementofcardiovascularriskthroughepigeneticbiomarkers AT laurentmetzinger managementofcardiovascularriskthroughepigeneticbiomarkers AT stefanodefranciscis managementofcardiovascularriskthroughepigeneticbiomarkers AT raffaeleserra managementofcardiovascularriskthroughepigeneticbiomarkers |
_version_ |
1716778592432553984 |